BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancer patients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancer patients treated with cyclophosphamide and anthracycline, but there is little data for malignant lymphoma. We conducted a prospective phase 2 study at a single institution to clarify the efficacy and safety of palonosetron in lymphoma patients. METHODS: Chemotherapy-naïve lymphoma patients who were treated with highly emetogenic chemotherapy (HEC) received a single intravenous bolus of palonosetron, 0.75 mg/body, before chemotherapy on day 1 during the first course of chemotherapy. The occurrence of CINV was assessed using the Multinational Association for Supportive Care in Cancer (MASCC) antiemesis tool, which was recorded by patients during the first course of chemotherapy. RESULTS: A total of 59 patients were enrolled, and 49 patients were eligible and evaluated. The complete response (CR) rate was 93.9% (95% confidence interval 83.1-98.7%) at 0-120 h post-chemotherapy. The proportion of patients who developed nausea of any grade and vomiting at 0-120 h post-chemotherapy was 34.7 and 6.1%, respectively. Although treatment-related adverse events were observed in 36 (73.5%) patients, these were mild and they recovered by the next cycle of chemotherapy. CONCLUSION: The present study demonstrated that a single dose of palonosetron was highly effective and safe for the prevention of CINV in lymphoma patients.
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancerpatients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancerpatients treated with cyclophosphamide and anthracycline, but there is little data for malignant lymphoma. We conducted a prospective phase 2 study at a single institution to clarify the efficacy and safety of palonosetron in lymphomapatients. METHODS: Chemotherapy-naïve lymphomapatients who were treated with highly emetogenic chemotherapy (HEC) received a single intravenous bolus of palonosetron, 0.75 mg/body, before chemotherapy on day 1 during the first course of chemotherapy. The occurrence of CINV was assessed using the Multinational Association for Supportive Care in Cancer (MASCC) antiemesis tool, which was recorded by patients during the first course of chemotherapy. RESULTS: A total of 59 patients were enrolled, and 49 patients were eligible and evaluated. The complete response (CR) rate was 93.9% (95% confidence interval 83.1-98.7%) at 0-120 h post-chemotherapy. The proportion of patients who developed nausea of any grade and vomiting at 0-120 h post-chemotherapy was 34.7 and 6.1%, respectively. Although treatment-related adverse events were observed in 36 (73.5%) patients, these were mild and they recovered by the next cycle of chemotherapy. CONCLUSION: The present study demonstrated that a single dose of palonosetron was highly effective and safe for the prevention of CINV in lymphomapatients.
Authors: K Suzuki; T Yamanaka; H Hashimoto; Y Shimada; K Arata; R Matsui; K Goto; T Takiguchi; F Ohyanagi; Y Kogure; N Nogami; M Nakao; K Takeda; K Azuma; S Nagase; T Hayashi; K Fujiwara; T Shimada; N Seki; N Yamamoto Journal: Ann Oncol Date: 2016-06-29 Impact factor: 32.976
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: N J Talley; S F Phillips; A Haddad; L J Miller; C Twomey; A R Zinsmeister; R L MacCarty; A Ciociola Journal: Dig Dis Sci Date: 1990-04 Impact factor: 3.199
Authors: Marko Popovic; David G Warr; Carlo Deangelis; May Tsao; Kelvin K W Chan; Michael Poon; Cheryl Yip; Natalie Pulenzas; Henry Lam; Liying Zhang; Edward Chow Journal: Support Care Cancer Date: 2014-03-04 Impact factor: 3.603
Authors: Alexander Molassiotis; Peter A Coventry; Carrie T Stricker; Caroline Clements; Beth Eaby; Luke Velders; Cynthia Rittenberg; Richard J Gralla Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg Journal: Ann Oncol Date: 2014-03-05 Impact factor: 32.976